University of Nottingham

University of Nottingham

Stroke Medicine

The clinical interests of the Division are in the treatment of acute stroke, enhancing recovery and preventing recurrence; the following multicentre trials are coordinated by the Stroke Trials Unit: ultra-acute lowering of blood pressure before hospitalisation (RIGHT trial); hyperacute cooling/hypothermia (EU FP-7 trial); hyperacute tranexamic acid for primary intracerebral haemorrhage (HTA TICH-2 trial); acute lowering of BP in hospital (MRC ENOS trial of glyceryl trinitrate); acute intensive antiplatelets for preventing early recurrence (BHF-HTA TARDIS trial); prevention of post stroke cognitive impairment (TSA-AS PODCAST trial); chronic mobilisation of endogenous stem cells (RfPB STEMS-3 trial of granulocyte colony stimulating factor); the translational studies aim to identify a series of novel therapeutic targets that can subsequently be employed in clinical settings to prevent and/or reverse ischaemic injury-mediated breakdown of the blood-brain barrier and the ensuing formation of brain oedema which accounts for the majority of deaths within the first week after an ischaemic stroke; in this regard, the currently ongoing projects focus on pro-inflammatory cytokines, notably TNF-alpha and Interleukin-1beta; NADPH oxidase enzyme system and oxidative stress; matrix metalloproteinases, Plasminogen-plasmin system components; hypothermia.

Course modules

Assessment methods

Qualifications

Qualification Study mode Start month Fee Course duration
PhD Full-time - 2 years
PhD Part-time - 4 years
DM Full-time - 2 years
DM Part-time - 4 years
MPhil Full-time - 1 years
MPhil Part-time - 2 years

Campus details

Campus name Town Postcode Region Main campus Campus Partner
Queen's Medical Centre Nottingham NG7 2HA East Midlands

Get in touch

Remember to mention TARGETpostgrad when contacting universities.

Key information

Contact: 
Postgraduate Enquiries
Telephone number: 
+44 (0) 115 951 5559